Hikma Pharmaceuticals PLC
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Said Samih Taleb Darwazah
- Full Time Employees
- 9,400
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1 New Burlington Place London GL United Kingdom W1S 2HR
- IPO Date
- Feb 7, 2012
- Website
- hikma.com
- Similar Companies
- Business
- Hikma Pharmaceuticals PLC engages in the creation, production, commercialization, and distribution of a diverse portfolio encompassing generic, branded, and licensed pharmaceutical goods. The company delivers its offerings in a variety of final dosage formats, including oral, respiratory, sterile injectable, liquid, and solid preparations. Its operations are organized across three principal divisions: Injectables, Generics, and Branded. The Injectables segment focuses on providing critical generic and specialty injectable products primarily to healthcare institutions across North America, Europe, and the Middle East and North Africa (MENA) regions, where it stands as a leading supplier in key markets. The Generics segment caters to the North American retail market with a broad array of oral and other non-injectable generic and specialty products. The Branded segment supplies proprietary generic medicines and in-licensed treatments to both retail and hospital clients throughout the MENA region. Hikma's extensive product range addresses numerous therapeutic categories such as anti-infectives, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory conditions. The multinational firm maintains a significant presence across the United States, Europe, the Middle East, North Africa, and other international markets, leveraging a network of manufacturing and research facilities globally. Established in 1978 in Amman, Jordan, the company's global headquarters are situated in London, United Kingdom.
Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma
Hikma Pharmaceuticals Announces Major Expansion in Ohio, Creating 350 New Jobs and Investing $267 Million
Hikma Pharmaceuticals PLC (HKMPY) Sales/ Trading Statement Call Transcript
UK's Hikma Pharmaceuticals reiterates 2026 outlook despite higher costs from Iran war
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Prepared Remarks Transcript
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Transcript
Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US
Hikma Pharmaceuticals: Due a dose of confidence
Hikma Pharmaceuticals PLC (HKMPY) Shareholder/Analyst Call Transcript
Hikma Pharmaceuticals (OTCMKTS:HKMPY) Shares Up 0.9% – Should You Buy?
Hikma Pharmaceuticals PLC (HKMPF) Q2 2025 Pre Recorded Earnings Call Transcript
Hikma Pharmaceuticals PLC (HKMPF) Q2 2025 Q&A Earnings Call Transcript
Hikma Pharmaceuticals tumbles after injectables margin outlook cut
Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US
Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
Bio-Thera Solutions and Hikma Pharmaceuticals Announce FDA Approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
Hikma acquires Novugen's FDA-approved ANDA for trametinib
Hikma Pharmaceuticals PLC (HKMPF) Q4 2024 Earnings Call Pre-Recorded (Transcript)
Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg